title: Treatment of IgA nephropathy.
abstract: IgA nephropathy (Berger's disease) is the most common primary glomerulonephritis worldwide and was once equated with benign recurrent hematuria. Longer observation showed that 15% to 30% of patients progress to end-stage renal failure after 20 years of clinical manifestations. Because the pathogenesis remains enigmatic, therapy to ameliorate disease progression can not be disease-specific. Several approaches to treatment have generated increasing interest in the last few years, including angiotensin inhibition, glucocorticoids, fish oil, cyclophosphamide, tonsillectomy and mycophenolate mofetil. For patients reaching end-stage renal failure, recurrent disease after transplantation remains a clinically important problem, despite immunosuppression since engraftment.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham, 35294-0006, USA. BJULIAN@NRTC.DOM.UAB.EDU
authors.forename: B A
authors.initials: BA
authors.lastname: Julian
mesh_terms: D002986:Clinical Trials as Topic; D005922:Glomerulonephritis, IGA / Q000628:therapy*; D006801:Humans